TRLs in Pharmaceutical Development: A Detailed Walkthrough
In the realm of pharmaceuticals, Technology Readiness Levels (TRLs) serve as a critical pathway from initial research to the marketing of a new drug. Each level represents a significant step in the journey of drug development. Below is a detailed explanation of each TRL in the context of pharmaceuticals.
- TRL1 – Findings Reviewed: This initial stage involves reviewing existing research and findings, laying the groundwork for new pharmaceutical developments.
- TRL2 – Research Idea: At this stage, researchers formulate a specific research idea or hypothesis based on the initial findings.
- TRL3 – Design Proof of Concept: Scientists design experiments to prove the concept of the proposed pharmaceutical treatment.
- TRL4 – Demonstrate Proof of Concept: The proof of concept is demonstrated through initial laboratory experiments, validating the research idea.
- TRL5 – Pilot Drug Produced: A pilot version of the drug is produced, typically in small quantities, for preliminary testing.
- TRL6 – Phase 1 Clinical Trials: The drug enters Phase 1 clinical trials, where it is tested on a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects.
- TRL7 – Phase 2 Clinical Trials: In Phase 2 trials, the drug is given to a larger group of people to see if it is effective and to further evaluate its safety.
- TRL8 – New Drug Registration: After successful clinical trials, the drug goes through the process of registration, where it is thoroughly reviewed and approved by regulatory authorities for market release.
- TRL9 – Drug Distributed and Marketed: The final stage where the drug is fully approved, manufactured on a large scale, distributed, and marketed to the public.
Pharmaceutical TRLs
The progression of pharmaceuticals from TRL1 to TRL9 is a complex journey from theoretical research to a marketable drug.
The articles found on Rasph.com reflect the opinions of Rasph or its respective authors and in no way reflect opinions held by the European Commission (EC) or the European Innovation Council (EIC). The provided information aims to share perspectives that are valuable and can potentially inform applicants regarding grant funding schemes such as the EIC Accelerator, EIC Pathfinder, EIC Transition or related programs such as Innovate UK in the United Kingdom or the Small Business Innovation and Research grant (SBIR) in the United States.
The articles can also be a useful resource for other consultancies in the grant space as well as professional grant writers who are hired as freelancers or are part of a Small and Medium-sized Enterprise (SME). The EIC Accelerator is part of Horizon Europe (2021-2027) which has recently replaced the previous framework program Horizon 2020.
This article was written by ChatEIC. ChatEIC is an EIC Accelerator assistant that can advise on the writing of proposals, discuss current trends and create insightful articles on a variety of topics. The articles written by ChatEIC can contain inaccurate or outdated information.
Are you interested in hiring a writer to apply for grants in the EU?
Please feel free to reach out here: Contact
Are you looking for a training program to learn how to apply for the EIC Accelerator?
Find it here: Training
